Trial Profile

Phase 2 Randomized Placebo-Controlled Double-Blind Parallel Study to Evaluate Glucagon RTU (Glucagon Injection) Compared to Standard of Care for Prevention of Exercise-Induced Hypoglycemia During Regular Aerobic Exercise in Adults With T1D

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
15 Jun 2020 According to a Xeris Pharmaceuticals media release, Michael Riddell, PhD, (Senior Scientist, LMC Diabetes and Endocrinology, Professor & Graduate Program Director, School of Kinesiology and Health Science, Faculty of Health, York University) is the co-investigator of this trial.
15 Jun 2020 According to a Xeris Pharmaceuticals media release, the company anticipate an end-of-phase 2 meeting with the FDA later this year to discuss a clinical path forward for this program.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com